近期医药圈的两笔重磅交易,为眼科药物赛道注入强心剂:奥赛康子公司AskGene Pharma与将其自主研发的眼科双抗ASKG712(靶向VEGF/ANG-2抗体)在大中华地区、新加坡、泰国、马来西亚、印度尼西亚、越南、韩国及印度市场的独家权益授予Visara。信达生物将眼科药物VEGF/Ang-2双抗IBI324授权给了一家美国生物技术公司Ollin。这两款眼科双抗的跨境授权密集落地,印证眼科药物...
Source Link近期医药圈的两笔重磅交易,为眼科药物赛道注入强心剂:奥赛康子公司AskGene Pharma与将其自主研发的眼科双抗ASKG712(靶向VEGF/ANG-2抗体)在大中华地区、新加坡、泰国、马来西亚、印度尼西亚、越南、韩国及印度市场的独家权益授予Visara。信达生物将眼科药物VEGF/Ang-2双抗IBI324授权给了一家美国生物技术公司Ollin。这两款眼科双抗的跨境授权密集落地,印证眼科药物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.